{"id":29659,"date":"2024-09-19T15:44:23","date_gmt":"2024-09-19T10:14:23","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=29659"},"modified":"2024-09-24T18:27:56","modified_gmt":"2024-09-24T12:57:56","slug":"medtech-news-for-boston-scientific-philips-microbot-medical","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical","title":{"rendered":"Boston Scientific INGEVITY\u2122 gets Expanded Indication and acquires Silk Road Medical; FDA Approves Philips&#8217; LumiGuide Guidewire; Microbot Completes LIBERTY Trial Enrollment; Innovent Presents Data at ESMO 2024; Argon Medical Launches CLEANER Vac\u2122 System"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f4f372126e3\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f4f372126e3\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical\/#Boston_Scientific_Received_FDA_Approval_For_The_Expanded_Indication_of_INGEVITY%E2%84%A2_Pacing_Leads_Allowing_For_Conduction_System_Pacing_in_The_Left_Bundle_Branch_Area\" >Boston Scientific Received FDA Approval For The Expanded Indication of INGEVITY\u2122+ Pacing Leads, Allowing For Conduction System Pacing in The Left Bundle Branch Area&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical\/#Philips_Received_FDA_Approval_For_Its_Advanced_LumiGuide_Guidewire_and_Marked_The_Occasion_by_Treating_Its_1000th_Patient_With_The_Breakthrough_3D_Device_Guidance_Technology\" >Philips Received FDA Approval For Its Advanced LumiGuide Guidewire and Marked The Occasion by Treating Its 1000th Patient With The Breakthrough 3D Device Guidance Technology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical\/#Microbot_Medical_Announced_The_Successful_Enrollment_of_50_of_The_Patients_in_Its_Pivotal_Human_Clinical_Trial_For_The_LIBERTY_Endovascular_Robotic_Surgical_System\" >Microbot Medical Announced The Successful Enrollment of 50% of The Patients in Its Pivotal Human Clinical Trial For The LIBERTY Endovascular Robotic Surgical System&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical\/#Innovent_Delivered_Oral_Presentations_on_The_Clinical_Data_of_IBI354_in_Advanced_Ovarian_Cancer_Breast_Cancer_and_Other_Solid_Tumors_at_the_2024_ESMO_Congress\" >Innovent Delivered Oral Presentations on The Clinical Data of IBI354 in Advanced Ovarian Cancer, Breast Cancer, and Other Solid Tumors at the 2024 ESMO Congress<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical\/#Boston_Scientific_Closed_Acquisition_of_Silk_Road_Medical_Inc\" >Boston Scientific Closed Acquisition of Silk Road Medical, Inc.&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical\/#Argon_Medical_Launched_CLEANER_Vac%E2%84%A2_Thrombectomy_System_to_Remove_Blood_Clot_in_The_Peripheral_Venous_Vasculature\" >Argon Medical Launched CLEANER Vac\u2122 Thrombectomy System to Remove Blood Clot in The Peripheral Venous Vasculature&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-boston-scientific-received-fda-approval-for-the-expanded-indication-of-ingevity-pacing-leads-allowing-for-conduction-system-pacing-in-the-left-bundle-branch-area-nbsp\"><span class=\"ez-toc-section\" id=\"Boston_Scientific_Received_FDA_Approval_For_The_Expanded_Indication_of_INGEVITY%E2%84%A2_Pacing_Leads_Allowing_For_Conduction_System_Pacing_in_The_Left_Bundle_Branch_Area\"><\/span><strong>Boston Scientific Received FDA Approval For The Expanded Indication of INGEVITY\u2122+ Pacing Leads, Allowing For Conduction System Pacing in The Left Bundle Branch Area&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On September 17, 2024, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval to expand the indication for the current-generation INGEVITY\u2122+ Pacing Leads, which are thin wires placed inside the heart and connected to an implantable device. The approval now includes conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA) when connected to a single- or dual-chamber pacemaker.<\/p>\n\n\n\n<p>Pacing of the LBBA was introduced as an alternative to traditional right ventricular pacing for treating symptomatic bradycardia, a condition characterized by an abnormally slow heart rate. This approach utilized the heart&#8217;s natural electrical system by placing a lead in the LBBA of the heart&#8217;s conduction system. By doing so, it aimed to promote greater ventricular synchrony and potentially reduce the long-term risk of heart failure commonly associated with traditional right ventricular pacing.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;This approval strengthens our broader initiative to provide physicians with LBBA-specific tools and educational resources, while reinforcing our commitment to developing safe and effective pacing technologies,&#8221; said Scott Olson, senior vice president and president, Cardiac Rhythm Management and Diagnostics, Boston Scientific. &#8220;We believe the expanded indication for the INGEVITY+ Pacing Lead will enhance the implant experience for physicians and connect this technology to the growing number of patients who can benefit from LBBA pacing.\u201d<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;This expanded indication provides physicians using the INGEVITY+ Pacing Lead the flexibility to determine the most appropriate pacing strategy based on individual patient characteristics,&#8221; said Kenneth Stein, M.D., Senior Vice President and Global Chief Medical Officer, Boston Scientific. &#8220;Data has demonstrated this lead to be safe and effective for LBBA pacing \u2013 a rapidly growing pacing technique \u2013 allowing us to provide a new therapeutic option on a proven lead that will further the quality of patient care.&#8221;<\/p>\n<\/blockquote>\n\n\n\n<p>The FDA was provided with clinical evidence to support the expanded indication, which included data from about 400 patients in the INSIGHT-LBBA study, where INGEVITY+ pacing leads had been previously implanted in the LBBA for anti-bradycardia pacing, along with results from bench testing and LATITUDE\u2122 Programming System data.<\/p>\n\n\n\n<p>During its implantation, the INGEVITY+ Pacing Lead was guided by a stylet, allowing for optimal positioning within the heart and ensuring continuous pacing along with impedance monitoring for secure placement. The expanded indication was granted after the release of Boston Scientific\u2019s CSP portfolio, which included tools such as the OneLINK\u2122 Splitter Cable, INGEVITY+ Helix Locking Tool, and pacing delivery catheters, all aimed at supporting the safe implantation of the INGEVITY+ lead in the LBBA. The lead had initially received FDA approval in 2019 for use with pacemakers and defibrillators.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/pacemakers-market\" class=\"ek-link\"><strong>Pacemakers Market Report<\/strong><\/a>\u201d, the global pacemakers market was valued at <strong>USD 4.88 billion<\/strong> in 2023, growing at a <strong>CAGR of 5.85%<\/strong> during the forecast period from 2024 to 2030, to reach <strong>USD 6.84 billion<\/strong> by 2030. The demand for pacemakers is primarily motivated due to the rise in cardiovascular diseases (CVDs), superior treatment outcomes of sudden cardiac arrests, and growing technological advancements among others during the forecast period.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-philips-received-fda-approval-for-its-advanced-lumiguide-guidewire-and-marked-the-occasion-by-treating-its-1000th-patient-with-the-breakthrough-3d-device-guidance-technology\"><span class=\"ez-toc-section\" id=\"Philips_Received_FDA_Approval_For_Its_Advanced_LumiGuide_Guidewire_and_Marked_The_Occasion_by_Treating_Its_1000th_Patient_With_The_Breakthrough_3D_Device_Guidance_Technology\"><\/span><strong>Philips Received FDA Approval For Its Advanced LumiGuide Guidewire and Marked The Occasion by Treating Its 1000th Patient With The Breakthrough 3D Device Guidance Technology<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On September 17, 2024, Royal Philips, a global leader in health technology, announced the FDA approval and launch of the 160cm version of its LumiGuide endovascular navigation wire. The enhanced LumiGuide guidewire, which incorporated the company\u2019s groundbreaking Fiber Optic RealShape (FORS) technology, was first utilized by Professor Carlos Timaran, MD, an internationally recognized vascular surgeon. The procedure, involved a complex aortic aneurysm repair, and marked the 1000th patient treated with FORS technology since its initial clinical use in 2020. This new, longer FORS-enabled LumiGuide Navigation Wire had provided US clinicians with the capability to visualize a broader range of catheters, thereby extending the technology\u2019s application to more patients across American centers.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cThe new enhanced Philips LumiGuide navigation guidewire represents a significant leap forward in endovascular surgery, offering unprecedented 3D visualization and precision during complex procedures, as the first to use this guidewire for a complex aortic repair, I experienced firsthand its potential to revolutionize how we approach minimally invasive vascular interventions. The patient who underwent this groundbreaking procedure is doing well, further validating the efficacy of this innovative technology.\u201d said Carlos Timaran, MD, an internationally recognized expert in advanced endovascular techniques.<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cLumiGuide unlocks the color visualization of wires, catheters, and patient anatomies in 3D from any angle, including simultaneous angles to generate \u2018virtual biplane\u2019 images. Combined with device navigation viewed from angles physically unachievable using conventional C-arm systems, it has already been shown to improve workflows, reduce procedure times, and decrease patient and staff radiation dose,&#8221; said Dr. Atul Gupta, Chief Medical Officer for Diagnosis and Treatment at Philips and a practicing interventional radiologist.<\/p>\n<\/blockquote>\n\n\n\n<p>Traditionally, minimally-invasive surgeries typically required doctors to use live X-ray imaging (fluoroscopy) to guide interventional devices like catheters inside patients. This method presented radiation risks for both patients and physicians and only delivered grayscale, 2D images. The LumiGuide system, powered by Philips\u2019 FORS technology, had transformed this practice by providing real-time, 3D, color images of guidewires and catheters from any angle with minimal radiation exposure. Philips\u2019 FORS technology had eased navigation through tortuous vessels, allowing complex aortic repair procedures to be performed 37% faster and using 70% less X-ray imaging. The introduction of the 160cm LumiGuide wire had enhanced reach and catheter loading capabilities compared to the 120cm guidewire, enabling US physicians to utilize 3D device guidance with a greater variety of catheters and extending the technology\u2019s use to more patients and procedures.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/coronary-guidewires-market\" class=\"ek-link\"><strong>Coronary Guidewires Market Report<\/strong><\/a>\u201d, the global coronary guidewire market is estimated to grow at a <strong>CAGR of 5.7%<\/strong> during the forecast period from 2024 to 2030. The demand for coronary guidewire is primarily being boosted due to the increasing prevalence of coronary artery disease (CAD) across the globe. Further, the rising adoption of advanced and innovative technologies, the rising awareness about minimally invasive heart surgeries, the increasing geriatric population prone to various cardiovascular diseases, rising figures of various risk factors causing coronary heart diseases, and the increasing product launches and approval among others, are thereby contributing to the overall growth of the coronary guidewire market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-microbot-medical-announced-the-successful-enrollment-of-50-of-the-patients-in-its-pivotal-human-clinical-trial-for-the-liberty-endovascular-robotic-surgical-system-nbsp\"><span class=\"ez-toc-section\" id=\"Microbot_Medical_Announced_The_Successful_Enrollment_of_50_of_The_Patients_in_Its_Pivotal_Human_Clinical_Trial_For_The_LIBERTY_Endovascular_Robotic_Surgical_System\"><\/span><strong>Microbot Medical Announced The Successful Enrollment of 50% of The Patients in Its Pivotal Human Clinical Trial For The LIBERTY Endovascular Robotic Surgical System&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On September 17, 2024, Microbot Medical Inc., the developer of the LIBERTY\u00ae Endovascular Robotic Surgical System, announced that it successfully reached the midpoint of the ACCESS-PVI pivotal human clinical trial. The company had enrolled and completed follow-up for 50% of the patients participating in the trial to evaluate the LIBERTY\u00ae Endovascular Robotic Surgical System. The company had anticipated completing enrollment and follow-up in the fourth quarter of 2024 and filing its 510(k) submission with the U.S. Food and Drug Administration (FDA) by the end of 2024.<\/p>\n\n\n\n<p>ACCESS-PVI is a prospective, multi-center, single-arm, clinical trial designed to evaluate the performance and safety of LIBERTY\u00ae in human subjects undergoing Peripheral Vascular Interventions. The trial is expected to support the future 510(k) submission to the FDA and, when approved, subsequent commercialization.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cI have performed several procedures using LIBERTY\u00ae during the trial and I am continuing to enroll patients,\u201d commented Dr. Dmitry Rabkin, MD, PhD (Assistant Chief, Division of Angiography &amp; Interventional Radiology) at Brigham and Women&#8217;s Hospital in Boston. \u201cI am pleased with the ease of use and quick set-up of the robot, requiring, in my experience, a very short learning curve.\u201d<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cWe are excited by both the achievement of this milestone, and physician feedback. We remain on track to complete the trial and subsequent submission of the 510(k) to the FDA before year end,\u201d commented Juan Diaz-Cartelle, MD, Chief Medical Officer.<\/p>\n<\/blockquote>\n\n\n\n<p>The Investigational LIBERTY\u00ae Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY\u00ae Endovascular Robotic Surgical System\u2019s remote operation has the potential to be the first system to democratize endovascular interventional procedures.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-robotic-system-market\" class=\"ek-link\"><strong>Surgical Robotic System Market Report<\/strong><\/a>\u201d, the global surgical robotic systems market was valued at <strong>USD 5.02 billion<\/strong> in 2023, growing at a <strong>CAGR of 11.50%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 9.64 billion<\/strong> by 2030. The demand for surgical robotic systems is witnessing a surge due to increasing surgical procedures which can be attributed to various factors such as the increasing geriatric population who form a big part of the at-risk population for prostate cancer, valvular diseases, endometriosis among other diseases, growing need for robot-assisted surgery systems due to the growing inclination towards minimally invasive surgical approaches, and the innovation in product development which is paving the way for miniaturized surgical robots ultimately contributing in the overall growth of the Surgical Robotic Systems market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-innovent-delivered-oral-presentations-on-the-clinical-data-of-ibi354-in-advanced-ovarian-cancer-breast-cancer-and-other-solid-tumors-at-the-2024-esmo-congress\"><span class=\"ez-toc-section\" id=\"Innovent_Delivered_Oral_Presentations_on_The_Clinical_Data_of_IBI354_in_Advanced_Ovarian_Cancer_Breast_Cancer_and_Other_Solid_Tumors_at_the_2024_ESMO_Congress\"><\/span><strong>Innovent Delivered Oral Presentations on The Clinical Data of IBI354 in Advanced Ovarian Cancer, Breast Cancer, and Other Solid Tumors at the 2024 ESMO Congress<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On September 18, 2024, Innovent Biologics, Inc., known for its development, manufacturing, and commercialization of high-quality treatments for various serious diseases, revealed that the clinical data for IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) in advanced solid tumors was showcased at the <a href=\"https:\/\/www.delveinsight.com\/esmo-conference-2024\">2024 ESMO Congress<\/a>.<\/p>\n\n\n\n<p>The data presented was from a Phase 1\/2 study designed to assess the safety, tolerability, and preliminary efficacy of IBI354 in patients with advanced solid tumors. A total of 368 participants were enrolled in the study, receiving various doses of IBI354 monotherapy. This cohort included 178 individuals with breast cancer, 92 with ovarian cancer, 38 with colorectal cancer, and 60 with other types of tumors. Of these participants, 42.7% had previously undergone five or more systemic treatment regimens.<\/p>\n\n\n\n<p>IBI354 monotherapy demonstrated an excellent safety profile. The dosage was escalated to 18mg without any dose-limiting toxicity (DLT) events observed. The most common treatment-related adverse events (TRAEs) were nausea, decreased white blood cell count, and anemia. Interstitial lung disease (ILD) occurred in only 1.6% of patients, all at grade 1 severity. Overall, 21.5% of patients experienced TRAEs of grade 3 or higher, 2.4% had TRAEs that led to dose reduction, and 1.6% experienced TRAEs that resulted in discontinuation. No TRAEs led to death.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Doctor Daphne Day from the Medical Oncology Department at Monash Health in Melbourne, Australia, stated, \u201cBreast cancer is the second most commonly diagnosed cancer globally, the most common cancer in women, and a cause of cancer-related deaths. HER2 amplification or overexpression has been proven to play a significant role in the occurrence and progression of breast cancer, underscoring the importance of HER2-directed therapy. IBI354, as an anti-HER2 monoclonal antibody-camptothecin derivative conjugate, has shown promising preliminary results, with meaningful objective response and disease control rates in HER2-positive and -low breast cancer. Additionally, IBI354 has demonstrated excellent clinical safety and tolerability. Existing clinical data suggest that IBI354 has substantial development potential in the breast cancer population.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-robotic-system-market\" class=\"ek-link\"><strong>Cancer Monoclonal Antibodies Market Report<\/strong><\/a>\u201d, the cancer monoclonal antibodies market was valued at <strong>USD 80.59 billion<\/strong> in 2023, growing at a <strong>CAGR of 10% <\/strong>during the forecast period from 2024 to 2030 to reach <strong>USD 156.59 billion<\/strong> by 2030. The demand for cancer monoclonal antibodies is primarily being boosted owing to the rising cases of cancers, the growing number of risk factors for cancers such as smoking, exposure to radiation, faulty lifestyle, and others, rising research and developmental activities by market players, during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-boston-scientific-closed-acquisition-of-silk-road-medical-inc-nbsp\"><span class=\"ez-toc-section\" id=\"Boston_Scientific_Closed_Acquisition_of_Silk_Road_Medical_Inc\"><\/span><strong>Boston Scientific Closed Acquisition of Silk Road Medical, Inc.&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On September 17, 2024, Boston Scientific Corporation announced the completion of its acquisition of Silk Road Medical, Inc., a medical device company known for pioneering a new approach to stroke prevention and treating carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR).<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the innovative TCAR platform to a greater number of physicians and their patients through our significant commercial reach,&#8221; said Cat Jennings, president, Vascular, Peripheral Interventions, Boston Scientific. &#8220;The integration of the TCAR platform into our portfolio means we can offer a treatment option for patients suffering from carotid artery disease that can reduce the risk of stroke and lead to improved patient outcomes.&#8221;<\/p>\n<\/blockquote>\n\n\n\n<p>The acquisition included a purchase price of $27.50 per share, resulting in an enterprise value of approximately $1.18 billion. The impact on Boston Scientific&#8217;s adjusted earnings per share was expected to be immaterial in 2024 and 2025, with a positive effect anticipated thereafter. However, the impact on GAAP earnings per share was projected to be less accretive or potentially dilutive, due to amortization expenses and acquisition-related net charges.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/minimally-invasive-surgical-mis-devices-market\" class=\"ek-link\">Minimally Invasive Surgical (MIS) Devices Market Report<\/a>\u201d, the global MIS devices market was valued at <strong>USD 28,873.25 million <\/strong>in 2023, growing at a <strong>CAGR of 7.38%<\/strong> during the forecast period from 2024 to 2030, to reach <strong>USD 42,499 million<\/strong> by 2030. The MIS devices market is witnessing positive market growth owing to factors such as the rising prevalence of various cancers such as lung cancer which accounted for the highest number of cancer-related deaths and highest cancer incidence in 2023, and other indications such as cardiovascular diseases, and neurodegenerative diseases among others. Furthermore, the presence of factors such as growth in the aging population wherein age plays a key role in the development of various indications is another factor driving the growth of the MIS devices market. Moreover, the technological advancements in product development such as the development of surgical robots are further driving the MIS devices market as new products are gaining regulatory approvals and are entering the market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-argon-medical-launched-cleaner-vac-thrombectomy-system-to-remove-blood-clot-in-the-peripheral-venous-vasculature-nbsp\"><span class=\"ez-toc-section\" id=\"Argon_Medical_Launched_CLEANER_Vac%E2%84%A2_Thrombectomy_System_to_Remove_Blood_Clot_in_The_Peripheral_Venous_Vasculature\"><\/span><strong>Argon Medical Launched CLEANER Vac\u2122 Thrombectomy System to Remove Blood Clot in The Peripheral Venous Vasculature&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On September 16, 2024, Argon Medical Devices, a prominent provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the launch of the CLEANER Vac\u2122 Thrombectomy System. This new system was designed for the removal of blood clots from the peripheral venous vasculature.&nbsp;<\/p>\n\n\n\n<p>The CLEANER Vac Thrombectomy System is a disposable, large-bore aspiration system designed to quickly and effectively remove blood clots, also known as thrombus, from vessels with restricted blood flow. The device empowers physicians to manually control powered aspiration, enabling procedures with precise clot removal that may minimize vessel damage and reduce blood loss.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cRemoving thrombus from the venous anatomy can be very challenging depending on the patient\u2019s condition. Interventionalists need a simple and intuitive tool that allows them to easily navigate through the vasculature to the treatment area and control the removal of any obstructive thrombus. The streamlined design of the CLEANER Vac enables easy assembly, quick navigation, and efficient treatment, making it a welcomed treatment option for patients with this disease state.\u201d said Fakhir Elmasri, Interventional Radiologist, Lakeland Vascular Institute in Lakeland. Fl. Dr. Elmasri was the first physician in the United States to treat a patient with the CLEANER Vac Thrombectomy System.<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cWe are committed to advancing healthcare and we are excited to deliver the newest thrombectomy solution to interventionalists who prioritize efficient, successful outcomes for their patients. The CLEANER Vac Thrombectomy System is a testament to our dedication to improving treatment for this disease state, and we are confident this device will easily integrate into the current standard of care,\u201d said George Leondis, President &amp; CEO, Argon Medical.<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cNearly 900,000 people in the United States are diagnosed with problematic blood clots in the venous system, every year, leading to between 60,000 and 100,000 deaths annually1. The CLEANER Vac Thrombectomy System offers physicians more control to remove those clots and the streamlined design can simplify traditionally complex procedures,\u201d said Tom Younker, Senior Vice President of Global Marketing, Argon Medical.<\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-vascular-devices-market\"><strong>Peripheral Vascular Devices Market Report<\/strong><\/a>\u201d, the global peripheral vascular devices market size was valued at <strong>USD 9 billion<\/strong> in 2023, and it is expected to continue growing at a <strong>CAGR of 7.88%<\/strong> from 2024 to 2030. The demand for peripheral vascular devices is witnessing a surge due to rising prevalence of peripheral vascular diseases (PVDs), including peripheral artery disease (PAD) and deep vein thrombosis (DVT), due to aging populations and increasing rates of diabetes and hypertension, technological advancements in device design, such as the development of minimally invasive techniques, increasing awareness and diagnosis of vascular conditions lead to higher treatment rates and ultimately contributing in the overall growth of the peripheral vascular devices market during the forecast period from 2024 to 2030.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston Scientific Received FDA Approval For The Expanded Indication of INGEVITY\u2122+ Pacing Leads, Allowing For Conduction System Pacing in The Left Bundle Branch Area&nbsp; On September 17, 2024, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval to expand the indication for the current-generation INGEVITY\u2122+ Pacing Leads, which are thin wires placed inside [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":29662,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[22284,22283,704,2753,17021,16975,17037,19085,20747,19028],"industry":[17226],"therapeutic_areas":[17242],"class_list":["post-29659","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cancer-monoclonal-antibodies","tag-coronary-guidewires","tag-fda","tag-medical-device","tag-medical-devices-market","tag-medtech-market","tag-pacemakers","tag-pacemakers-market","tag-surgical-robotic-system-market","tag-surgical-robotic-systems","industry-medical-devices","therapeutic_areas-cardiovascular-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Boston Scientific, Philips, Microbot Medical<\/title>\n<meta name=\"description\" content=\"Boston Scientific\u2019s INGEVITY\u2122+; Philips\u2019 LumiGuide Guidewire; Microbot Medical\u2019s LIBERTY Endovascular Robotic Surgical System\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Boston Scientific, Philips, Microbot Medical\" \/>\n<meta property=\"og:description\" content=\"Boston Scientific\u2019s INGEVITY\u2122+; Philips\u2019 LumiGuide Guidewire; Microbot Medical\u2019s LIBERTY Endovascular Robotic Surgical System\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-19T10:14:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-24T12:57:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/19154400\/medtech-news-for-boston-scientific-philips-microbot-medical.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Boston Scientific, Philips, Microbot Medical","description":"Boston Scientific\u2019s INGEVITY\u2122+; Philips\u2019 LumiGuide Guidewire; Microbot Medical\u2019s LIBERTY Endovascular Robotic Surgical System","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Boston Scientific, Philips, Microbot Medical","og_description":"Boston Scientific\u2019s INGEVITY\u2122+; Philips\u2019 LumiGuide Guidewire; Microbot Medical\u2019s LIBERTY Endovascular Robotic Surgical System","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-09-19T10:14:23+00:00","article_modified_time":"2024-09-24T12:57:56+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/19154400\/medtech-news-for-boston-scientific-philips-microbot-medical.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical","name":"MedTech News | Boston Scientific, Philips, Microbot Medical","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/19154400\/medtech-news-for-boston-scientific-philips-microbot-medical.png","datePublished":"2024-09-19T10:14:23+00:00","dateModified":"2024-09-24T12:57:56+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Boston Scientific\u2019s INGEVITY\u2122+; Philips\u2019 LumiGuide Guidewire; Microbot Medical\u2019s LIBERTY Endovascular Robotic Surgical System","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-boston-scientific-philips-microbot-medical#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/19154400\/medtech-news-for-boston-scientific-philips-microbot-medical.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/19154400\/medtech-news-for-boston-scientific-philips-microbot-medical.png","width":772,"height":482,"caption":"medtech-news-for-boston-scientific-philips-microbot-medical"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/19154400\/medtech-news-for-boston-scientific-philips-microbot-medical-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer Monoclonal Antibodies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Coronary Guidewires<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pacemakers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pacemakers Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Surgical Robotic System Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Surgical Robotic Systems<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer Monoclonal Antibodies<\/span>","<span class=\"advgb-post-tax-term\">Coronary Guidewires<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Pacemakers<\/span>","<span class=\"advgb-post-tax-term\">Pacemakers Market<\/span>","<span class=\"advgb-post-tax-term\">Surgical Robotic System Market<\/span>","<span class=\"advgb-post-tax-term\">Surgical Robotic Systems<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Sep 19, 2024","modified":"Updated on Sep 24, 2024"},"absolute_dates_time":{"created":"Posted on Sep 19, 2024 3:44 pm","modified":"Updated on Sep 24, 2024 6:27 pm"},"featured_img_caption":"medtech-news-for-boston-scientific-philips-microbot-medical","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=29659"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29659\/revisions"}],"predecessor-version":[{"id":29754,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29659\/revisions\/29754"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/29662"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=29659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=29659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=29659"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=29659"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=29659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}